Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

New cyclopentenopyridine derivatives from Banyu active as ETA antagonists

Sep. 1, 1999

CytRx initiates phase I/II study of Flocor for treatment of acute lung injury

Sep. 1, 1999

ETA antagonist TA-0201 protects against deleterious effects of MI in dogs

Aug. 31, 1999

Preclinical and mechanism of action studies support efficacy of the NHE-1 inhibitor cariporide

Aug. 31, 1999

Final results of REACH-1 now in, support efficacy of bosentan in CHF

Aug. 30, 1999

Still in the news: vasopeptidase inhibitor omapatrilat a protagonist in Barcelona

Aug. 30, 1999

The aging heart: Should we refine management?

Aug. 27, 1999

Cardioselective potassium channel blocker advances to phase II trials at HMR

Aug. 25, 1999

FDA approves phase III protocol for Cypros' Cordox

Aug. 25, 1999

Tezosentan, a novel ETA/ETB antagonist for parenteral treatment of acute hemodynamic conditions

Aug. 24, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
Coreterra Therapeutics patents agents for schizophrenia
BioWorld Science
Work at Coreterra Therapeutics Inc. has led to the discovery of new thienyl compounds intended for potential use in the treatment of schizophrenia.